Ovarian Cancer

Hypermethylation is a common, relatively early event in ovarian tumorigenesis

Published in Women's Health Weekly, December 9th, 2004

Oncologists with the Fox Chase Cancer Center, Philadelphia, have determined that hypermethylation is a common, relatively early event in ovarian tumorigenesis that can be detected in serum DNA of patients with Stage I or II tumors or in cytologically negative peritoneal fluid.

"Because existing surgical and management methods can consistently cure only early-stage ovarian cancer, novel strategies for early detection are required," stated I.I. Decaceres and colleagues. "Silencing of tumor suppressor genes such as p16(INK4a), VHL, and hMLH1 have established promoter hypermethylation as a common mechanism for tumor suppressor inactivation in human cancer and as a promising...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2004-12-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry